BioSyent Releases Results for Third Quarter and First Nine Months of 2015
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 11/11/15 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three and nine months ending September 30, 2015. Key highlights include:
"During the third quarter of 2015, while the Company''s existing products continued to grow, the Company also signed an exlusive license agreement to sell the Cysview® product in Canada," commented Rene Goehrum, President and CEO of BioSyent. "Cysview® is an innovative technology that aids in the diagnosis and management of non-muscle-invasive bladder cancer. Cysview® is synergistic with our existing product portfolio and represents a significant investment in our Hospital Business Unit. The marketing authorization for Cysview® was recently successfully transferred to BioSyent Pharma from our partner, Photocure ASA. The Company is now in final preparations for the launch of Cysview® to the Canadian market."
The CEO presentation on the Q3 2015 Results is available at the following link: .
The Company''s Interim Unaudited Condensed Consolidated Financial Statements and Management''s Discussion & Analysis will be posted on on November 11, 2015.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 13,966,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contacts:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 1398617
Anzahl Zeichen: 2757
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioSyent Releases Results for Third Quarter and First Nine Months of 2015
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSyent Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
